ReviewOncology letters2025
Role and clinical significance of the DNA methylation of 14-3-3σ in cancer (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of 14-3-3 Proteins as Binding Partners of TRP Channels.Journal of chemical information and modeling · 2026Article
- Exploring 14-3-3ζ: insights into its role in cancer mechanisms and future therapeutic applications.Hereditas · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 14-3-3 family of proteins are phosphoserine/phosphothreonine-binding proteins. 14-3-3σ (SFN) is a subtype of the 14-3-3 family and is widely present in all tissues and organs of eukaryotes. SFN can regulate various biological activities, such as cell growth, cell division, cell death and cell migration, by binding to different client proteins. These diverse biological functions make SFN a candidate protein that may play a notable role in the development of various diseases. However, its mechanism of action remains unclear, and its role in different diseases is still controversial. DNA methylation is an important epigenetic modification. DNA methylation, under the catalysis of DNA-related modification enzymes, affects gene expression regulation, including the silencing of tumor suppressor genes, oncogene activation, genome stability and the tumor microenvironment. In the present review, how SFN DNA methylation promotes or blocks the carcinogenesis and tumor progression of various cancer types is discussed. The potential clinical value of SFN as a tumor suppressor or cancer-promoting factor in different cancer types for precision cancer medicine is also highlighted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.